CONTENTS
· Invitation
· Faculty
· Scientific Agenda
· Continuing
  Medical Education
· Who Should Attend?
· Objectives
· Registration
· General Information
· Hotel
  Accommodations
· Organizer

Dear Colleagues,

It is with great pleasure that we invite you to attend the inaugural conference, Perspectives in Urologic Oncology: A Case-Based Conference to Enhance Patient Management of Prostate, Renal and Bladder Cancers, to be held September 28-29, 2007 in Chicago, Illinois.

This case-based conference is the combination and expansion of two great urologic oncology conferences – Perspectives in Prostate Cancer and Challenging Cases in Urology. It will be a forum where urologists and medical/radiation oncologists can come together to learn and share their clinical experiences through both lecture presentations and interactive case discussions.

Our panel of world-renowned experts will touch on the most salient aspects of prostate, renal, and bladder cancers. We will discuss the status of the latest treatment modalities as well as promising emerging approaches to therapy. The emphasis will be to discuss the areas of controversy through vigorous discussion and debate using information from clinical trials as applicable. The speakers have all been selected because of their strong therapy area experience and ability to communicate effectively.

Our ultimate goal is to provide you with the information needed to optimize the care of your urologic oncology patients and to direct your attention to those trends and evolutions that are worth watching. We will specifically concentrate on the dilemmas and areas where we lack consensus.

With the beauty of Chicago in the fall in full color, we hope you will join us for what is sure to be an outstanding interactive event with many lively discussions!

Sincerely,

Eric J. Small, MD
Mark S. Soloway, MD

Friday, September 28, 2007

8:30 am
Welcome and introduction
Eric J. Small, MD and Mark S. Soloway, MD

Prostate Cancer

Session I: Surveillance and surgery
Moderator: William J. Catalona, MD

8:35 am
The role of active surveillance for low risk prostate cancer
Laurence H. Klotz, MD

8:55 am
State-of-the-art radiotherapy: Which type for which patient?
Mack Roach, III, MD

9:15 am
T3 disease: Is there a role for surgery?
William J. Catalona, MD and Mack Roach, III, MD

9:35 am
PSA only relapse following radical prostatectomy
William J. Catalona, MD

9:55 am
Questions

10:00 am
Break

Session II: Challenging cases in prostate cancer I: Prognosis and surgery
Moderator: Eric J. Small, MD
Panel: William J. Catalona, MD
Laurence H. Klotz, MD
Mack Roach, III, MD

10:20 am
Cases
Eric J. Small, MD

11:30 am
Lunch

Session III: Systemic and radiation therapy
Moderator: Eric J. Small, MD

12:30 pm
The best type and timing of androgen deprivation therapies
Charles Ryan, MD

12:50 pm
Update: Hormone refractory prostate cancer/chemotherapy in the metastatic setting
Eric J. Small, MD

1:10 pm
Side effects of systemic therapy
Charles Ryan, MD

1:30 pm
Emerging therapeutic agents in prostate cancer
Eric J. Small, MD

1:50 pm
Questions

Session IV: Challenging cases in prostate cancer II: Systemic and radiation therapies
Moderator: Mark S. Soloway, MD
Panel: William J. Catalona, MD
Mack Roach, III, MD
Charles Ryan, MD
Eric J. Small, MD

1:55 pm
Cases
Mark S. Soloway, MD

2:55 pm
Break

Renal Cancer

Session V: Prognosis and surgery
Moderator: Arthur I. Sagalowsky, MD

3:15 pm
Prognostic and molecular markers: Are they ready for the clinic?
Robert H. Weiss, MD

3:35 pm
Laparoscopic approach to small renal masses
Inderbir S. Gill, MD

3:55 pm Alternative approaches
to small renal masses: Radiofrequency and cryotherapy ablation
Raymond J. Leveillee, MD

4:15 pm
Questions

Session VI: Challenging cases in renal cancer I: Prognosis, surgical and ablative options
Moderator: Mark S. Soloway, MD
Panel: Inderbir S. Gill, MD Raymond J. Leveillee, MD Robert H. Weiss, MD

4:20 pm
Cases
Mark S. Soloway, MD

5:30 pm
Adjourn

Saturday, September 29, 2007

9:00 am
Welcome and introduction

Session VII: Systemic therapy
Moderator: Eric J. Small, MD

9:05 am
Targeted therapies for renal cancer and the role of adjuvant therapy
Robert Dreicer, MD, FACP

9:25 am
Emerging therapeutic agents in renal cancer
Robert Dreicer, MD, FACP

9:45 am
Questions

Session VIII: Challenging cases in renal cancer II: Implementing new systemic therapies
Moderator: Mark S. Soloway, MD
Panel: Robert Dreicer, MD, FACP

9:50 am
Cases
Mark S. Soloway, MD

10:20 am
Break

Bladder Cancer

Session IX: Risk stratification and non-surgical therapies
Moderator: Arthur I. Sagalowsky, MD

10:40 am
Risk stratification for all patients with bladder cancer
Arthur I. Sagalowsky, MD

11:00 am
Optimal management of Ta, T1 and CIS bladder cancer using intravesical therapy
Ashish M. Kamat, MD

11:20 am
Options after BCG therapy
Michael A. O’Donnell, MD, FACS

11:40 am
Questions

Session X: Challenging cases in stage
Ta-T1 bladder cancer
Moderator: Mark S. Soloway, MD
Panel: Ashish M. Kamat, MD Arthur I. Sagalowsky, MD

11:45 am
Cases
Mark S. Soloway, MD

12:45 pm
Lunch

Session XI: Surgical, systemic and radiation therapies
Moderator: Gary D. Steinberg, MD, FACS

1:45 pm
Debate: Chemotherapy for cT2 – cT3 bladder cancer Adjuvant chemotherapy post cystectomy
Gary D. Steinberg, MD, FACS
vs.
Neoadjuvant chemotherapy
Mark S. Soloway, MD

2:05 pm
Selective bladder preservation: Who, when and why?
John J. Coen, MD

2:25 pm
Emerging therapeutic agents in bladder cancer
Daniel P. Petrylak, MD

2:45 pm
Questions

2:50 pm
Break

Session XII: Challenging cases in stage T2+ bladder cancer
Moderator: Eric J. Small, MD
Panel: Michael A. O’Donnell, MD, FACS
Daniel P. Petrylak, MD
Arthur I. Sagalowsky, MD
Gary D. Steinberg, MD, FACS

3:15 pm
Cases
Eric J. Small, MD

4:15 pm
Adjourn

Imedex®, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Imedex, Inc designates this educational activity for a maximum 12.50 of AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

This conference is intended for urologists, medical oncologists, radiation oncologists, surgeons and other healthcare providers involved or interested in the management of renal, bladder and prostate cancer. No specialized knowledge other than a basic familiarity with the principles of oncology is needed to participate in this event.

After successful completion of this course, attendees should be able to:

• Comment on the newest trends in imaging and use of prognostic markers for renal, bladder and prostate cancers
• Implement state-of-the-art surgical advancements in renal, bladder and prostate cancers
• Evaluate novel treatment strategies and newly approved agents for renal, bladder and prostate cancers
• Improve case management between the urologist and medical/radiation/surgical oncologist in renal, bladder and prostate cancers
• Apply contemporary chemotherapies for metastatic disease in renal, bladder and prostate cancers
• Identify emerging therapies in a wide variety of urologic cancers

Click here to register for this program

REGISTRATION FEES
Discounted . . . . . . . . . . . . . . . . . . . . . . . . . . $245.00
If payment received by August 3, 2007

Regular . . . . . . . . . . . . . . . . . . . . . . . . . . . . .$345.00
If payment received by September 20, 2007

Full/Onsite: . . . . . . . . . . . . . . . . . . . . . . . . . . $445.00
To register after September 20, 2007

Nurses/Residents/Students* . . . . . . . . . . . . . . . $99.00
*proof of eligibility must accompany registration

Group discount (physicians only)* . . . . . . . . . . . -$50.00
*cannot be combined with any other discounts

To Register: You may register online by September 20, 2007 or by calling Imedex at +1 (678) 242 0906. To qualify for special registration fees, registration and full payment must be received by Imedex by the dates specified.

Group Discounts: Each one of multiple registrants from the same institute or practice each receive a $50 discount off the published registration fees, provided all registration forms and payments are received together. Only one discount will apply per physician. Discounts are not available for Nurses, Residents or Students.

Payment: To pre-register, registration and payment must be received no later than September 20, 2007. Please register onsite after this date. Contact Imedex at +1 (678) 242 0906 or visit our website at www.imedex.com to ensure the program is being held as scheduled and to confirm that the meeting is not full. Registration fees must be remitted by credit card, check, or wire transfer. Checks should be payable to Imedex. To pay via wire transfer, you must add $25 to each wire transaction to cover bank charges. Include the full name of the attendee and the name of the conference: Perspectives in Urologic Oncology #287. An attendee is not registered until full payment is received.

Wire to: Bank of America, ABA: 0260.0959.3, Account Info: Imedex, Inc., Account: 0000.0106.3308. If the wire originates outside the United States, please add this additional information: Clearing Bank: Bank of America, New York, Swift Code: BOFAUS3N, Clearing Account: 6550305831.

Registration Fee Inclusions: Registration fees include admittance to all scientific sessions, conference materials, processing of certificates of attendance or continuing medical education, and all event functions as specified in the program.

Cancellations: To cancel any portion of your registration, please send an email to meetings@imedex.com no later than September 20, 2007. Refunds are subject to a $75 USD administrative charge and will be made after the conference. Substitutions are accepted with written notification. No refunds will be made when cancellation occurs after September 20, 2007.

Discounted Airfares
Contact conference travel agent, Age of Travel, for assistance with your travel needs. Age of Travel can also accommodate pre- and post-conference extensions.

Tel.: 1 (800) 523 4954 or +1 (404) 591 7120
Email: imedex@ageoftravel.com

Conference Location and Registration
Wyndham Chicago
633 North St. Clair Street
Chicago, Illinois 60611
Tel.: +1 (312) 573 0300
Fax: +1 (312) 274 0164

The Registration and Information Desk will be staffed:
Friday, September 28, 2007 . . . . . . . . 7:30 am – 5:30 pm
Saturday, September 29, 2007 . . . . . . 8:30 am – 3:30 pm

Wyndham Chicago
633 North St. Clair Street
Chicago, Illinois 60611
Tel.: +1 (312) 573 0300
Fax: +1 (312) 274 0164

The Wyndham Chicago is an oasis of comfort and style in the heart of Chicago’s Magnificent Mile. Just one block off Michigan Avenue in a neighborhood full of world-class restaurants, shopping, museums and galleries. Lake Michigan, the Symphony Center and the Loop financial district are all nearby.

Settle into a spacious room or suite with a dazzling view of downtown Chicago. Enjoy thoughtful touches like high-speed Internet access and a cordless multi-line phone. Dine at the chic Caliterra Bar & Grille or unwind in the fitness center and indoor pool. Relax with a walk through our vibrant neighborhood - or let the concierge plan a special outing.

For the convenience of attendees, a limited number of rooms have been reserved until September 6, 2007 at a discounted rate of $279.00 single/double occupancy, plus tax, currently at 15.4%. This rate is not guaranteed outside the conference dates or after September 6, 2007.

To reserve your room please contact the Wyndham Chicago reservations department at +1 (800) 996 3426 or visit www.wyndham.com/groupevents/469lern/main.wnt. To receive the group rate, callers must identify themselves as being with the Perspectives in Urologic Oncology group. Reservation requests received after September 6, 2007 may not be guaranteed the group rate.

          4325 Alexander Drive
          Alpharetta, GA 30022-3740 USA
          Tel.: +1 (770) 751 7332
          Fax: +1 (770) 751 7334
          Email: meetings@imedex.com
          Web: www.imedex.com